版本:
中国

BRIEF-Albireo announces plans for Phase 3 clinical program of A4250 in patients with PFIC

May 18 Albireo Pharma Inc

* Albireo announces plans for Phase 3 clinical program of A4250 in patients with PFIC

* Albireo Pharma Inc says initiation of Phase 3 anticipated in second half of 2017

* Albireo Pharma - planned Phase 3 PFIC program includes single randomized, double blind, placebo controlled, multicenter, six-month treatment trial

* Albireo Pharma - planned Phase 3 PFIC program trial designed to enroll 60 patients Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐